Rapacuronium Pregnancy and Breastfeeding Warnings
Brand names: Raplon
Rapacuronium Pregnancy Warnings
Rapacuronium has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of fetotoxicity and increased resorption. There are no controlled data in human pregnancy. It has been reported that following a single maternal dose, there was a passage of low levels of rapacuronium across the placenta and slow elimination. Rapacuronium is only recommended for use during pregnancy if the potential benefit to the patient outweighs the potential risk to the fetus. This warning does not apply to the use of rapacuronium during Cesarean section. However, monitoring of the infant is recommended after delivery.
Rapacuronium Breastfeeding Warnings
There are no data on the excretion of rapacuronium into human milk. Because many drugs are excreted into human milk, caution is recommended if rapacuronium is to be used in a nursing mother.
References for pregnancy information
- Product Information. Raplon (rapacuronium). Organon. 2001;PROD.
References for breastfeeding information
- Product Information. Raplon (rapacuronium). Organon. 2001;PROD.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
